New epigenetic biomarkers to predict more aggressive forms of prostate cancer have been discovered by scientists at Australia’s Garvan Institute of Medical Research.
Breakthrough in predicting prostate cancer
Two decades of research has Australian scientists on the path to diagnosing aggressive forms of prostate cancer before it’s too late.
The painstaking discovery of new epigenetic biomarkers, or DNA features associated with abnormal cell division, is the work of senior staff at Sydney’s Garvan Institute.
Combined with traditional clinical tools, the group believe their findings will allow doctors to predict whether men will go on to develop more metastic and lethal forms of the disease and devise better treatment plans.
Globally, prostate cancer is the second-most common cancer for men. Following diagnosis, about 50 per cent of patients develop metastatic cancer during their lifetime.